Miss Ava Safaroghliazar
Research Assistant
School of Pharmacy and Biomedical Sciences
College of Health
| Year | Citation |
|---|---|
| 2026 | Safaroghli-Azar, A., Mekonnen, L. B., Lenjisa, J., Milne, R., & Wang, S. (2026). Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.. J Hematol Oncol, 19(1), 31. |
| 2025 | Safaroghli-azar, A., Mekonnen, L. B., Hassankhani, R., Lenjisa, J., Basnet, S. K. C., Batayneh, H., . . . Wang, S. (2025). A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer. Investigational New Drugs, 43(3), 728-741. Scopus1 WoS1 Europe PMC1 |
| 2023 | Safaroghli Azar, A., Emadi, F., Lenjisa, J., Mekonnen, L., & Wang, S. (2023). Kinase inhibitors: opportunities for small molecule anticancer immunotherapies. Drug Discovery Today, 28(5), 1-12. Scopus3 WoS4 Europe PMC1 |
Connect With Me
